ANCR
NEUTRALAnimalcare Director Increases Stake
The veterinary pharmaceuticals company has announced that a non-executive director has purchased additional shares in the business.
Animalcare Group
249.00GBX
0.00%
Market Cap
171.78M
Volume
30.95k
19% of avg
P/E Ratio
20.43
EPS (TTM)
12.19
Beta
0.34
Day Range
248.00p - 250.00p
52 Week Range
202.00p249.00p305.35p
249.00p
Upcoming Events
ANCR
NEUTRALAnimalcare Group Announces Major Shareholder Change
The retailer has announced a change in its major shareholder, with Liontrust Investment Partners LLP increasing its stake in the company.
ANCR
NEUTRALBlackRock Reduces Stake in Animalcare Group
The healthcare company has seen a reduction in the shareholding of major investor BlackRock.
ANCR
NEUTRALAnimalcare Group Sees Major Shareholding Change
The healthcare company has seen a significant change in its major shareholders.
ANCR
NEUTRALAnimalcare Group Announces Major Shareholder Change
The healthcare company has received notification of a change in major shareholding.
ANCR
GOODAnimalcare Reports Strong H1 2025 Results with Double-Digit Growth
This animal health business reports strong H1 results, with double-digit revenue and profit growth, driven by a successful acquisition and improved margins. However, modest organic growth and market challenges temper the outlook.
ANCR
NEUTRALAnimalcare partners to develop new treatment for equine 'sweet itch'
The veterinary company has entered into an agreement to develop and commercialise a novel biological treatment for a common equine skin condition, known as 'sweet itch'.
ANCR
NEUTRALAnimalcare Group Announces Upcoming Results and Presentations
The veterinary company will report its half-year results and host analyst and investor presentations in the coming weeks.
ANCR
NEUTRALAnimalcare Acquires VHH NGF Programme and Assets
The veterinary company has acquired a programme researching antibodies for treating pain in animals, expanding its pipeline of innovative products.
ANCR
VERY GOODAnimalcare Group Delivers Strong H1 Performance, Driven by Randlab Acquisition
The international animal health business delivered robust H1 results, driven by strong organic growth and the successful integration of its Australian equine acquisition.